Comparative Pharmacology
Head-to-head clinical analysis: DEPAKOTE CP versus SITAVIG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPAKOTE CP versus SITAVIG.
DEPAKOTE CP vs SITAVIG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Valproate increases GABA concentration in the brain by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase. It also blocks voltage-gated sodium channels and T-type calcium channels.
Sitavig (acyclovir) is a synthetic nucleoside analogue that inhibits viral DNA replication. It is phosphorylated to acyclovir triphosphate, which competitively inhibits viral DNA polymerase and incorporation into viral DNA, leading to chain termination.
250-500 mg orally twice daily, titrated by 250 mg/day every 3-7 days; maximum 60 mg/kg/day. Target trough serum concentration: 50-100 mcg/mL.
Topical: Apply one 50 mg buccal tablet to the upper gum above the incisor region once daily for 14 days.
None Documented
None Documented
Terminal elimination half-life is 9-16 hours (mean ~12 hours) in adults; prolonged in hepatic impairment, elderly, and neonates.
Terminal elimination half-life is approximately 20 hours in adults with normal renal function. In patients with renal impairment (CrCl <30 mL/min), half-life increases to up to 40 hours, necessitating dose adjustment.
Renal: 30-50% as glucuronide conjugates, 3% as unchanged drug; fecal: minimal; less than 3% excreted in bile.
Primarily renal; approximately 80% of the dose is excreted unchanged in urine within 24 hours. Minor fecal excretion (less than 10%).
Category C
Category C
Anticonvulsant
Anticonvulsant